Search

Displaying results 8041 - 8050 of 10000 in total
  1. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  2. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  3. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  4. Drug

    Epitizide

    go.drugbank.com/drugs/DB13989
    Experimental

    Epitizide is an agent, commonly found in combination [triamterene], used to produce diuresis.

  5. Drug

    Preimplantation factor

    go.drugbank.com/drugs/DB16301
    Investigational

    Preimplantation factor is under investigation in clinical trial NCT03593460 (Phase II Autoimmune Hepatitis).

  6. Drug

    P-nitrobiphenyl

    go.drugbank.com/drugs/DB12300
    ApprovedWithdrawn

    Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.

  7. Drug

    Menaquinone 7

    go.drugbank.com/drugs/DB13075
    Investigational

    Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children).

  8. Drug

    ZUBERITAMAB

    go.drugbank.com/drugs/DB19443
    Investigational

    Zuberitamab is under investigation in clinical trial NCT06642909 (A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy).

  9. Drug

    Deudextromethorphan

    go.drugbank.com/drugs/DB19054
    Investigational

    Deudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an

  10. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).